France’s accès précoce (early access) scheme is one of the most attractive routes to market in Europe. Manufacturers can make an innovative medicine available to patients before standard reimbursement, at a price they set themselves. For companies aiming to establish a strong international price point, the appeal is obvious.
That model is now under scrutiny. In July 2026, the French Senate’s Social Affairs Committee adopted a wide-ranging report on therapeutic innovation that makes 27 recommendations, several of which would reshape how early access works and how long it lasts. The report does not propose abolishing the scheme; it calls early access the cornerstone of France’s innovation policy. But it sets out a clear view: in some cases the freely set early access price is being used as leverage in price negotiations, and policymakers want to close that door.
Who is behind the report?
The report was produced by the Senate’s Social Security Evaluation and Control Mission (MECSS), a cross-party body within the Social Affairs Committee charged with auditing social security spending. Three senators from different political groups, Corinne Imbert, Émilienne Poumirol and Cathy Apourceau-Poly, led the work, which was examined by the MECSS on 7 July and adopted by the full committee on 8 July 2026.
The core concern: price anchoring and slow negotiations
The free early access price is not quite as free as it appears. Under the remise de débouclage (clawback rebate), manufacturers must repay the difference between the early access price and the final negotiated price once a permanent price is agreed. Partly as a result, the cost to the health insurance system has been relatively contained at €348 million in 2023.
The Senate’s concern lies elsewhere. The early access price can act as an anchor for negotiations with CEPS (Comité économique des produits de santé), the body that sets medicine prices, both in France and in other countries that reference French prices. And because a medicine in early access is already reimbursed and generating revenue, the manufacturer has less urgency to conclude a deal than one whose product earns nothing until it is priced.
The data support this concern. According to a November 2025 government evaluation cited in the report, the median CEPS negotiation for products that went through early access took 175 days, compared with 70 days for those that did not. Early access products also required a median of 11 negotiation sessions versus 7.
The knock-on effects are visible in how long products remain in the scheme. HAS reviews have found the average time a medicine spends in early access rose from 9 months in 2022 to 13 in 2023, and 17 today. More than 40% of the early access applications HAS receives are now renewals, some of them third or fourth renewals for products that have held marketing authorisation for years. The report notes that most renewals involve pre-authorisation products with immature data, and that abuse is confined to a minority of companies. But 12% of renewals are linked to price negotiations lasting more than 500 days, which the rapporteurs describe as a misuse of the scheme.
The Senate’s six key recommendations on early access
- A one-year cap on post-authorisation early access. Post- authorisation early access would be limited to 12 months following the HAS Transparency Committee’s standard assessment, extendable by up to six months at the manufacturer’s request with CEPS agreement. Notably, the rapporteurs present this as the moderate option: the Government proposed abolishing post-authorisation early access altogether in the last social security financing bill.
- Longer initial grants for pre-authorisation early access HAS could grant initial pre-authorisation early access for 18 months rather than 12 where clinical data allow, reducing the renewal burden on both companies and HAS.
- A permanent direct access scheme The experimental accès direct pathway would be made permanent and opened to products already reimbursed in the retail setting for at least one indication. The maximum negotiation period would start from the CEESP health-economic opinion where one is required, and a six-month extension would be possible with CEPS agreement. The aim is to make direct access a genuine alternative to post-authorisation early access.
- Price trajectories. Building on a proposal from the CEPS president, new products would receive an attractive, guaranteed launch price for a period linked to their ASMR rating, followed by steeper scheduled net price reductions over the product’s life. The report also wants the list price to converge with the net price by the end of market exclusivity. The trade-off for manufacturers is explicit: more predictability and a stronger launch price in exchange for faster price erosion once the product is established.
- Conditional assessments and stays of decision. Today, a promising product with immature data risks an ASMR V rating (no added benefit), which requires it to generate savings against comparators and can stall negotiations entirely. The report proposes allowing HAS to issue a temporary assessment pending further data, conditional on the manufacturer committing to provide it, and to defer its decision (sursis à statuer) where data are too immature to assess.
- A European negotiating alliance. The report calls for a coordinated European strategy to strengthen member states’ bargaining power on price. It situates this against the US Most Favored Nation policy, citing a finding that 64% of companies expect MFN to delay or cancel product launches in France within three years.
What this means for manufacturers
These are recommendations, not law. But Senate reports of this kind often feed directly into amendments to the annual social security financing bill (PLFSS), and the Government has already shown its appetite for reform. Companies with products in or approaching French early access should start planning now.
Assume a shorter revenue window. If the one-year cap is adopted, the post-authorisation early access period becomes a fixed runway rather than an open-ended bridge. CEPS dossiers, pricing strategies and internal approvals will need to be ready earlier, and forecasts that assume extended early access revenue should be stress-tested.
Rethink the role of the early access price. A high early access price has always carried claw back exposure. Under a time-limited regime, it will also carry less leverage: a negotiation that cannot outlast the early access period gives CEPS a stronger hand. International pricing strategies that rely on France as an early high-price reference may need revisiting.
Evaluate direct access as a real option. For products with mature data at authorisation, a permanent and broader direct access pathway could offer a faster, more predictable route than post-authorisation early access.
Model price trajectories. A guaranteed premium launch price is attractive, but steeper scheduled declines change the lifetime value of a French launch. Companies should model both scenarios and consider how a declining French price would interact with international reference pricing.
Plan evidence generation for immature data. Conditional assessments could spare promising products the ASMR V trap, but they come with a commitment to deliver further data. Evidence plans should be built with that obligation in mind.
Watch the European dimension. Coordinated European negotiation, combined with MFN pressure from the US, points toward a world in which French prices are increasingly part of a wider international negotiation rather than a standalone decision.
France’s early access scheme remains one of the most valuable tools available to manufacturers in Europe. The Senate’s message is that it should remain a route to patient access, not a tool for price negotiations. Companies that adapt their launch planning to that expectation now will be better placed whatever form the final reforms take.
Written by Johann Sanseau, Associate Consultant
